Literature DB >> 33830429

Current Analysis of Skeletal Phenotypes in Down Syndrome.

Jared R Thomas1, Randall J Roper2.   

Abstract

PURPOSE: Down syndrome (DS) is caused by trisomy 21 (Ts21) and results in skeletal deficits including shortened stature, low bone mineral density, and a predisposition to early onset osteoporosis. Ts21 causes significant alterations in skeletal development, morphology of the appendicular skeleton, bone homeostasis, age-related bone loss, and bone strength. However, the genetic or cellular origins of DS skeletal phenotypes remain unclear. RECENT
FINDINGS: New studies reveal a sexual dimorphism in characteristics and onset of skeletal deficits that differ between DS and typically developing individuals. Age-related bone loss occurs earlier in the DS as compared to general population. Perturbations of DS skeletal quality arise from alterations in cellular and molecular pathways affected by the overexpression of trisomic genes. Sex-specific alterations occur in critical developmental pathways that disrupt bone accrual, remodeling, and homeostasis and are compounded by aging, resulting in increased risks for osteopenia, osteoporosis, and fracture in individuals with DS.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bone mineral density; Down syndrome; Osteopenia; Osteoporosis; Trisomy 21

Mesh:

Year:  2021        PMID: 33830429      PMCID: PMC8316313          DOI: 10.1007/s11914-021-00674-y

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.163


  78 in total

1.  Isolated sonographic markers for detection of fetal Down syndrome in the second trimester of pregnancy.

Authors:  D A Nyberg; V L Souter; A El-Bastawissi; S Young; F Luthhardt; D A Luthy
Journal:  J Ultrasound Med       Date:  2001-10       Impact factor: 2.153

Review 2.  Aging and Down syndrome: implications for physical therapy.

Authors:  Robert C Barnhart; Barbara Connolly
Journal:  Phys Ther       Date:  2007-08-21

3.  Long bone growth in Down's syndrome.

Authors:  G L Rarick; I F Rapaport; V Seefeldt
Journal:  Am J Dis Child       Date:  1966-12

4.  Bone Mineral Density Distribution Curves in Spanish Adults With Down Syndrome.

Authors:  Ramón Costa; Alejandra Gullón; Rosa De Miguel; Diego Real de Asúa; Azucena Bautista; Clara García; Carmen Suarez; Santos Castañeda; Fernando Moldenhauer
Journal:  J Clin Densitom       Date:  2018-03-21       Impact factor: 2.617

5.  Regulation of osteoclast differentiation and function by the CaMK-CREB pathway.

Authors:  Kojiro Sato; Ayako Suematsu; Tomoki Nakashima; Sayaka Takemoto-Kimura; Kazuhiro Aoki; Yasuyuki Morishita; Hiroshi Asahara; Keiichi Ohya; Akira Yamaguchi; Toshiyuki Takai; Tatsuhiko Kodama; Talal A Chatila; Haruhiko Bito; Hiroshi Takayanagi
Journal:  Nat Med       Date:  2006-11-26       Impact factor: 53.440

Review 6.  Function and regulation of Dyrk1A: towards understanding Down syndrome.

Authors:  Joongkyu Park; Woo-Joo Song; Kwang Chul Chung
Journal:  Cell Mol Life Sci       Date:  2009-08-14       Impact factor: 9.261

7.  People with mental retardation have an increased prevalence of osteoporosis: a population study.

Authors:  J Center; H Beange; A McElduff
Journal:  Am J Ment Retard       Date:  1998-07

8.  Estimation of the number of people with Down syndrome in the United States.

Authors:  Gert de Graaf; Frank Buckley; Brian G Skotko
Journal:  Genet Med       Date:  2016-09-08       Impact factor: 8.822

9.  Downregulated Wnt/β-catenin signalling in the Down syndrome hippocampus.

Authors:  Simone Granno; Jonathon Nixon-Abell; Daniel C Berwick; Justin Tosh; George Heaton; Sultan Almudimeegh; Zenisha Nagda; Jean-Christophe Rain; Manuela Zanda; Vincent Plagnol; Victor L J Tybulewicz; Karen Cleverley; Frances K Wiseman; Elizabeth M C Fisher; Kirsten Harvey
Journal:  Sci Rep       Date:  2019-05-13       Impact factor: 4.379

10.  Single cell transcriptome in aneuploidies reveals mechanisms of gene dosage imbalance.

Authors:  Georgios Stamoulis; Marco Garieri; Periklis Makrythanasis; Audrey Letourneau; Michel Guipponi; Nikolaos Panousis; Frédérique Sloan-Béna; Emilie Falconnet; Pascale Ribaux; Christelle Borel; Federico Santoni; Stylianos E Antonarakis
Journal:  Nat Commun       Date:  2019-10-03       Impact factor: 14.919

View more
  3 in total

1.  Low bone mass and impaired fracture healing in mouse models of Trisomy21 (Down syndrome).

Authors:  Kirby M Sherman; Diarra K Williams; Casey A Welsh; Alexis M Cooper; Alyssa Falck; Shannon Huggins; Rihana S Bokhari; Dana Gaddy; Kent D McKelvey; Lindsay A Dawson; Larry J Suva
Journal:  Bone       Date:  2022-06-15       Impact factor: 4.626

2.  Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.

Authors:  Raza Jamal; Jonathan LaCombe; Roshni Patel; Matthew Blackwell; Jared R Thomas; Kourtney Sloan; Joseph M Wallace; Randall J Roper
Journal:  PLoS One       Date:  2022-02-23       Impact factor: 3.752

3.  Green Tea Catechins Modulate Skeletal Development with Effects Dependent on Dose, Time, and Structure in a down Syndrome Mouse Model.

Authors:  Sergi Llambrich; Rubèn González-Colom; Jens Wouters; Jorge Roldán; Sara Salassa; Kaat Wouters; Vicky Van Bulck; James Sharpe; Zsuzsanna Callaerts-Vegh; Greetje Vande Velde; Neus Martínez-Abadías
Journal:  Nutrients       Date:  2022-10-07       Impact factor: 6.706

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.